EGFR Exon 20 Insertion Mutation:Research Status and New Treatment Strategies

VernacularTitle:EGFR外显子20插入突变:研究现状与治疗新策略
Author: TIAN MENGWEI ¹ ; WANG NA ; DOU ZHANJUN ; SONG XIA ; ZHANG XIA
Author Information

1. 030001 太原,山西医科大学第二临床医学院
Keywords: Lung neoplasms; Epidermal growth factor receptor; Exon 20 insertion mutation; Targeted therapy
From: Chinese Journal of Lung Cancer 2024;27(8):579-592
CountryChina
Language:Chinese
Abstract: In non-small cell lung cancer(NSCLC),as an improtant oncogenic driver gene,epidermal growth factor receptor exon 20 insertion(EGFR ex20ins)has a unique protein structure and is primarily drug-resistant to tradi-tional EGFR-tyrosine kinase inhibitors(EGFR-TKIs).In recent years,exploration of targeted therapy for EGFR ex20ins has never stopped.Firstly Mobocertinib and Amivantamab obtained approval from U.S.Food and Drug Administration(FDA)for EGFR ex20ins mutant NSCLC patients,then other drugs,such as Sunvozertinib,made breakthroughs and combination therapies also obtained gains.Multi-pronged measures are hopeful to overcome EGFR ex20ins drug resistance.As men-tioned above,it's definitely important to gain deeper understanding of molecular mechanism of EGFR ex20ins and assess ef-fect and difference between novel drugs.This review is devoted to make a summary about newest achievement so to provide valuable reference about precise therapy for patients with EGFR ex20ins.